GONAL-F RFF REDI-JECT 900 UNIT PEN
GONAL-F RFF REDI-JECT 900 UNIT PEN has a NADAC acquisition cost of $1,873.34, though hospitals typically charge significantly more than this wholesale benchmark for the same medication.
About the analyst
Kevin Nyk analyzes hospital pricing data at BillRazor Research. He specializes in Medicare reimbursement patterns and chargemaster pricing across U.S. hospitals. Expertise: hospital pricing, Medicare rates, chargemaster analysis.
GONAL-F RFF REDI-JECT is a fertility medication containing follitropin alfa used to stimulate ovarian follicle development in assisted reproductive treatments. This specialty drug typically requires prior authorization and charges significantly above Medicare benchmarks, creating potential coverage variations across different insurance plans.
No credit card required. Results in 60 seconds.
Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.
What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.
Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.